SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Tularik Inc. (TLRK)

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who started this subject11/4/2003 8:14:55 AM
From: nigel bates   of 598
 
Tularik Announces Public Offering of Common Stock
Tuesday November 4, 7:42 am ET

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 4, 2003--Tularik Inc. (Nasdaq:TLRK - News) today announced that it plans to offer 5 million shares of its common stock in an underwritten public offering pursuant to an effective shelf registration statement. The company also intends to grant an option to the underwriters to purchase up to an additional 750,000 shares of common stock to cover over-allotments, if any. All of the shares are being sold by Tularik.

Goldman, Sachs & Co. is the book-running and lead manager for this offering. SG Cowen Securities Corporation, UBS Securities LLC and SunTrust Robinson Humphrey are the co-managers.

This communication shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

Copies of the preliminary prospectus supplement may be obtained from the Prospectus Department of Goldman, Sachs & Co. (85 Broad Street, New York, New York 10004, telephone 212-902-1171, fax 212-902-9316).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext